Slavin S - Search Results

1

The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice.

Gross DJ, Reibstein I, Weiss L, Slavin S, Stein I, Neeman M, Abramovitch R, Benjamin LE. Gross DJ, et al. Among authors: slavin s. Clin Cancer Res. 1999 Nov;5(11):3669-75. Clin Cancer Res. 1999. PMID: 10589785

2

The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.

Gross DJ, Weiss L, Reibstein I, Hedlund G, Dahlén E, Rapoport MJ, Slavin S. Gross DJ, et al. Among authors: slavin s. Int Immunopharmacol. 2001 Jun;1(6):1131-9. doi: 10.1016/s1567-5769(01)00042-x. Int Immunopharmacol. 2001. PMID: 11407307 Review.

3

Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.

Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Gross DJ, et al. Among authors: slavin s. Diabetologia. 1994 Dec;37(12):1195-201. doi: 10.1007/BF00399792. Diabetologia. 1994. PMID: 7895948

4

Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes.

Slavin S, Sidi H, Weiss L, Rosenman E, Kalland T, Gross D. Slavin S, et al. Diabetes Metab Rev. 1993 Dec;9(4):311-5. doi: 10.1002/dmr.5610090411. Diabetes Metab Rev. 1993. PMID: 7924828 Review. No abstract available.

5

Prevention and treatment of type I diabetes in NOD mice by linomide.

Slavin S, Gross D, Weiss L. Slavin S, et al. Transplant Proc. 1995 Dec;27(6):3240. Transplant Proc. 1995. PMID: 8539933 No abstract available.

6

Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide).

Slavin S, Weiss L, Xia W, Gross DJ. Slavin S, et al. Cell Transplant. 1996 Nov-Dec;5(6):627-30. doi: 10.1177/096368979600500605. Cell Transplant. 1996. PMID: 8951220

7

Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment.

Gross DJ, Weiss L, Reibstein I, van den Brand J, Okamoto H, Clark A, Slavin S. Gross DJ, et al. Among authors: slavin s. Endocrinology. 1998 May;139(5):2369-74. doi: 10.1210/endo.139.5.5997. Endocrinology. 1998. PMID: 9564847

8

Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin.

Weiss L, Slavin S. Weiss L, et al. Among authors: slavin s. Bone Marrow Transplant. 1999 Jun;23(11):1139-43. doi: 10.1038/sj.bmt.1701784. Bone Marrow Transplant. 1999. PMID: 10382953

9

Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.

Weiss L, Reich S, Slavin S. Weiss L, et al. Among authors: slavin s. Cancer Invest. 1992;10(1):19-26. doi: 10.3109/07357909209032785. Cancer Invest. 1992. PMID: 1735011

10

Effect of total lymphoid irradiation on natural killer cells and cytotoxic and primed T lymphocytes.

Weiss L, Slavin S. Weiss L, et al. Among authors: slavin s. Isr J Med Sci. 1994 Apr;30(4):253-9. Isr J Med Sci. 1994. PMID: 8175324

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

768 results

Search Page

Filters